|
Business Model and Commercialization Strategy
| Two-Pronged Business Model |
 |
| with others |
on our own |
Rapid Value Added &
Short-Term Revenues
- Collaborations / alliances
- Pheromics library available selectively for licensing / partnering
|
Long-Term Revenues
- Self-developed products for licensing / partnering
- Products generated through collaborations / alliances
|
The Pharmaceutical Industry's Need for New Sources of Drug Candidates
The genomics era generated a large number of drug targets, tools, and
enabling technologies. However, there is a desperate need in the
pharmaceutical industry for new sources of drug candidates.
Small-molecule drugs remain the mainstay of the pharmaceutical industry and
are by far more attractive than biologics. However, it is widely recognized
that the primary ways to generate small molecules - combinatorial chemistry
libraries and rationale drug design - do not yield the number and quality of
drug candidates to fill the pharmaceutical industry's pipeline needs.
Natural compounds have provided a rich source of drug candidates; in fact,
many successful therapeutic products, including >50% of anticancer drugs,
are derived from natural compounds. However, the existing natural compounds
libraries have known drawbacks since the starting materials are extracts and
drug discovery relies on empirical testing. Additionally, the primary
existing sources - plants and microorganisms - have been mined extensively.
Therefore, the current efficiency of these efforts is low.
Alydar, with its novel drug-product platform of scaffolds based on an
untapped source of natural compounds, is poised to fill the pharmaceutical
industry's needs for new sources of drug candidates.
|
 |
